The race is on to release the first proteomics-based ovarian cancer diagnostic: This week, Ciphergen announced that it hopes to translate a collaborative ovarian cancer study into a commercial assay “by year-end.” Meanwhile, at last week’s IBC Biomarker conference, Lance Liotta of the NCI-FDA clinical proteomics program announced that his group — which he co-directs with Emanuel Petricoin — is “now gathering patients” for a blinded clinical trial that compares the predictability of protein patterns to CA125 for ovarian cancer recurrence.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The president of France's National Research Agency has resigned, according to Nature News.

A senator wants a "right-to-try" provision in the US Food and Drug Administration funding bill, but an ethicist says at Stat News that it would undermine the role of clinical trials.

In PNAS this week: red algae Porphyra umbicalis genome, deep neural network model for sequencing peptides, and more.

The Guardian's Barbara Ellen has tried out some DNA testing services to see whether they provide valuable information.